Haopeng Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haopeng Yang has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Michael R. Green
The University of Texas MD Anderson Cancer Center
55 shared publications - Jared Henderson
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas
51 shared publications - Estela Rojas
Department of Lymphoma and Myeloma University of Texas MD Anderson Cancer Center Houston Texas
43 shared publications - Sydney Parsons
University of Texas MD Anderson Cancer Center 1 Department of Lymphoma and Myeloma Houston, Texas
43 shared publications - Vida Ravanmehr
Department of Lymphoma and Myeloma University of Texas MD Anderson Cancer Center Houston Texas
32 shared publications - Adam E. Richardson
AbbVie Inc 1 N. Waukegan Rd. North Chicago Illinois
31 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (39)
Structural and functional divergence of cancer hotspot mutations in CREBBP
CREBBP is among the most frequently mutated genes in human cancer and encodes a lysine acetyltransferase (KAT) protein that acetylates histones and nonhistone proteins to drive transcriptional activation. Mutations of CREBBP most frequently result in missense changes affecting the active site within the KAT domain. However, there has not yet been comprehensive biochemical, structural, and functional studies to determine the impact of recurrent KAT-domain variants. Here we show that the most frequently mutated residue of CREBBP , arginine 1446, alters the stability of acetyl-CoA binding within the cofactor-binding pocket but retains detectable acetyltransferase activity for a variety of substrates including histones. In contrast, other recurrently mutated residues affect the catalytic center within the KAT domain and result in a catalytically dead protein with a profound loss of histone acetylation and enhancer activity. These results highlight functionally divergent classes of CREBBP mutations depending on the position of the mutated residue within KAT domain.
- 22 September 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (39)
Open AccessStructural and functional divergence of cancer hotspot mutations in CREBBP
CREBBP is among the most frequently mutated genes in human cancer and encodes a lysine acetyltransferase (KAT) protein that acetylates histones and nonhistone proteins to drive transcriptional activation. Mutations of CREBBP most frequently result in missense changes affecting the active site within the KAT domain. However, there has not yet been comprehensive biochemical, structural, and functional studies to determine the impact of recurrent KAT-domain variants. Here we show that the most frequently mutated residue of CREBBP , arginine 1446, alters the stability of acetyl-CoA binding within the cofactor-binding pocket but retains detectable acetyltransferase activity for a variety of substrates including histones. In contrast, other recurrently mutated residues affect the catalytic center within the KAT domain and result in a catalytically dead protein with a profound loss of histone acetylation and enhancer activity. These results highlight functionally divergent classes of CREBBP mutations depending on the position of the mutated residue within KAT domain.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Supplementary Figure S5: Comparison of copy number alteration frequencies between post-CART19 and CART19-naïve models. Statistical comparison of the frequency of DNA copy number alterations between post-CAR T and CAR-naïve PDX models. Lesions correspond to GISTIC peaks shown in Supplementary Figure S1. *Fisher exact P < 0.05.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Supplementary Figure S5: Comparison of copy number alteration frequencies between post-CART19 and CART19-naïve models. Statistical comparison of the frequency of DNA copy number alterations between post-CAR T and CAR-naïve PDX models. Lesions correspond to GISTIC peaks shown in Supplementary Figure S1. *Fisher exact P < 0.05.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Molecular characteristics of 48 cases LBCL PDX from MD Anderson.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Molecular characteristics of 48 cases LBCL PDX from MD Anderson.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Differentially expressed genes between CD19-positive and CD19-negative PDX.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Differentially expressed genes between CD19-positive and CD19-negative PDX.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Supplementary Figure S4: Immunohistochemical staining of the murine macrophage marker F4/80. IHC corresponding to Figure 5D showing zoomed out images of H&E, CD4 IHC and CD8 IHC, together with IHC staining for the myeloid marker F4/80.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Supplementary Figure S4: Immunohistochemical staining of the murine macrophage marker F4/80. IHC corresponding to Figure 5D showing zoomed out images of H&E, CD4 IHC and CD8 IHC, together with IHC staining for the myeloid marker F4/80.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Supplementary Figure S2: Lollipop plot of MYD88 and CD79B mutations from PDX models. Plots show the frequency of protein coding mutations in MYD88 (above) and CD79B (below), including hotspots at L252 and Y196, respectively. The cell of origin (purple, ABC; yellow, GCB) and LymphGen subtype for cases with MYD88 and/or CD79B mutations are summarized on the right.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Supplementary Figure S2: Lollipop plot of MYD88 and CD79B mutations from PDX models. Plots show the frequency of protein coding mutations in MYD88 (above) and CD79B (below), including hotspots at L252 and Y196, respectively. The cell of origin (purple, ABC; yellow, GCB) and LymphGen subtype for cases with MYD88 and/or CD79B mutations are summarized on the right.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Clinical features of 48 cases LBCL PDX from MD Anderson.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Clinical features of 48 cases LBCL PDX from MD Anderson.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Supplementary Figure S3: Gating hierarchy for Figure 5A. Cells shown in Figure 5A have been gated on intact single cells by forward scatter, side scatter and autofluorescence, and viable cells using viability dye.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Supplementary Figure S3: Gating hierarchy for Figure 5A. Cells shown in Figure 5A have been gated on intact single cells by forward scatter, side scatter and autofluorescence, and viable cells using viability dye.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Differentially expressed genes between post-CART19 and CART19-naïve models.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Differentially expressed genes between post-CART19 and CART19-naïve models.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Supplementary Figure S6: Flow cytometry gating hierarchy for Figure 7B. Cells shown in figure 7B are gated on viable lymphocytes and singlets by forward and side scatter.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma
Supplementary Figure S6: Flow cytometry gating hierarchy for Figure 7B. Cells shown in figure 7B are gated on viable lymphocytes and singlets by forward and side scatter.